CAMP4 Therapeutics (CAMP) Financials

Camp4 Therapeutics (NASDAQ:CAMP) remains in a development-stage financial profile: revenue is growing, but the company continues to generate substantial operating losses and consume cash. The latest quarter also included a significant non-operating expense that sharply increased the reported net loss.

Q2 2026 revenue increased to $1.8 million from $1.3 million in Q1 2026 and $1.5 million in Q2 2025. Because the company reported no cost of revenue in the periods provided, gross profit matched revenue. However, revenue remains well below the company’s quarterly operating expense base of $15.2 million, resulting in an operating loss of $13.4 million.

Research and development spending rose to $10.8 million in Q2 from $10.2 million in Q1 and $10.3 million a year earlier. This spending supports Camp4’s pipeline, but it also means the company is unlikely to reach profitability without substantially higher revenue, successful development milestones, or additional financing.

Cash generation remains a key concern. Operating cash outflow increased from $11.0 million in Q1 2026 to $12.7 million in Q2. Cash and equivalents declined from $99.2 million at the end of Q1 to $86.4 million at the end of Q2, although the company also held $730,000 of restricted cash. At the Q2 operating cash-burn rate, cash on hand provides a rough runway of less than two years, before considering changes in spending, milestone payments, financing activity, or working capital.

• Revenue momentum improved: Q2 2026 revenue rose approximately 37% sequentially and 19% year over year, continuing the company’s transition from periods of minimal or zero revenue in 2024 to recurring quarterly revenue.
• Cash resources remain meaningful: Camp4 reported $86.4 million of cash and equivalents plus $730,000 of restricted cash at June 30, 2026, compared with only $2.5 million of cash at September 30, 2024.
• Capital spending is modest: Q2 property, plant and equipment purchases totaled only $129,000, limiting the amount of cash tied up in capital expenditures.
• R&D investment remains elevated: research and development expense increased to $10.8 million in Q2 2026. This may support pipeline advancement, but investors will need evidence that the spending is producing clinical or commercial progress.
• Reported revenue has been volatile: quarterly revenue increased from $350,000 in Q3 2023 to $1.8 million in Q2 2026, but the business still lacks a long record of stable, self-sustaining revenue.
• Working-capital obligations are increasing: current deferred revenue reached $13.0 million and noncurrent deferred revenue totaled $1.5 million in Q2. These balances can represent future revenue obligations rather than immediately available earnings.
• Losses remain substantial: Q2 2026 net loss was $33.5 million, or $0.58 per share, compared with a $18.3 million loss in Q1. The quarterly loss was more than 18 times reported revenue.
• A large non-operating expense distorted Q2 results: other expense was $21.0 million in Q2, compared with $6.2 million in Q1. The cash-flow statement included $23.0 million of non-cash adjustments, suggesting that at least part of the charge may not represent immediate cash usage, but it still materially reduced reported equity and earnings.
• Cash burn is continuing: operating cash flow has been negative in every period provided from Q1 2024 through Q2 2026, including $12.7 million of operating cash outflow in the latest quarter.
• Balance-sheet risk has increased: total liabilities rose to $94.1 million in Q2 from $74.6 million in Q1, while shareholders’ equity turned negative at approximately $693,000. The company’s accumulated deficit also reached $344.0 million.

Camp4’s improving revenue and substantial cash balance are constructive, but they are currently outweighed by recurring losses, negative operating cash flow, and a deteriorating Q2 balance sheet. Investors should closely monitor cash burn, the explanation for the large non-operating expense, pipeline milestones, and whether future capital needs lead to additional dilution.